股价表现 - Cytek Biosciences, Inc. (CTKB) 过去四周股价上涨0.7%，收盘价为$6.91[1] - 分析师对CTKB的盈利前景持乐观态度，强烈认为公司有能力报告比他们之前预测的更好的收益，这加强了看涨观点[4],[9] 价格目标 - 根据华尔街分析师的短期价格目标，CTKB的平均估值为$10.20，潜在上涨幅度为47.6%[2] - 分析师的价格目标虽然是投资者追捧的指标，但仅仅依靠这一指标做投资决策可能不明智，因为分析师设定价格目标的能力和公正性一直存在质疑[3],[5],[8]

dra_schwartz/iStock via Getty Images Introduction Cytek Biosciences (NASDAQ:CTKB) is a leading cellular analysis instrument maker, with a primary focus on industry-leading Aurora flow cytometry platform. The flow cytometry field is mature with the lab instrument manufacturers holding significant market share, but Cytek has built a leading position thanks to offering the highest number of fluorescent detectors. This leads to deeper insights using a full spectrum of fluorescence. This niche leadership has all ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K ____________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40632 ____________________________________ CYTEK BIOSCIENCE ...

Cytek Biosciences, Inc.新设施 - Cytek Biosciences, Inc.宣布在中国无锡开设了一个新的5万平方英尺的设施，以满足全球对综合细胞分析解决方案日益增长的需求[1] - 该无锡设施不仅增强了Cytek的制造能力，还容纳了Cytek无锡的运营、研发、市场营销、人力资源和销售团队[2] Cytek的技术创新 - Cytek是光谱流式细胞术的先驱者，推出了第一个商业化的基于荧光的流式细胞术平台，实现了40种颜色，有效改变了科学家对流式细胞术可能性的认知[3]

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2023 Earnings Conference Call February 28, 2024 5:00 PM ET Company Participants Paul Goodson – Investor Relations Wenbin Jiang – Chief Executive Officer Patrik Jeanmonod – Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs David Westenberg - Piper Sandler Tejas Savant - Morgan Stanley Steven Mah - TD Cowen Mason Carrico - Stephens Operator Good day and thank you for standing by. Welcome to the Cytek Biosciences Fourth Quarter 2023 Earn ...

财务表现 - Cytek Biosciences在2023年第四季度的总收入为$58.6百万，较去年同期增长21%[9] - Cytek Biosciences在2023年第四季度的毛利润为$33.7百万，较去年同期增长15%[4] - Cytek Biosciences在2023年第四季度的调整后EBITDA为$11.0百万，较去年同期增长[10] 支出情况 - Cytek Biosciences在2023年第四季度的研发支出为$10.9百万，较去年同期增长[6] - Cytek Biosciences在2023年第四季度的营销支出为$11.6百万，较去年同期增长[7] 预测展望 - Cytek Biosciences预计2024年全年总收入将在$203百万至$213百万之间，增长5%至10%[20] 公司财务状况 - Cytek Biosciences, Inc.在2023年的产品销售收入为157,089千美元，服务销售收入为36,298千美元[30][31] - Cytek Biosciences, Inc.在2023年的总营收为193,387千美元，毛利为110,069千美元[31] - Cytek Biosciences, Inc.在2023年的总资产为495,187千美元，总负债为101,304千美元，股东权益为393,883千美元[32][33]

Cytek Biosciences, Inc. (CTKB)业绩预测 - Cytek Biosciences, Inc. (CTKB) 预计在2023年12月报告的季度业绩中，盈利将同比下降，但营收将增长[1] - 如果关键数据超过预期，股价可能会上涨，反之则可能下跌[2] - 分析师最近对该公司的季度盈利预期进行了下调，显示出他们对公司前景的重新评估[5] - Zacks Earnings ESP 模型比较了最准确的估计值和 Zacks 共识估计值，用于预测实际盈利与预期的偏差[8]

公司介绍 - Cytek Biosciences, Inc. (Nasdaq: CTKB)是一家领先的细胞分析解决方案公司[1] - Cytek Biosciences的核心仪器包括Cytek Aurora™和Northern Lights™系统，以及Cytek Aurora™ CS细胞分选器[2] - Cytek Biosciences的产品仅供研究使用，不适用于诊断程序[3] - Cytek Biosciences使用其网站、LinkedIn页面和X（以前是Twitter）账户作为信息发布渠道[4]

公司介绍 - Cytek Biosciences, Inc. (Nasdaq: CTKB)是一家领先的细胞分析解决方案公司[1] 产品介绍 - Cytek Biosciences的核心仪器包括Cytek Aurora™和Northern Lights™系统，以及细胞分选器Cytek Aurora™ CS，Cytek Orion™试剂混合制备系统，Amnis®和Guava®品牌的流式细胞仪和成像产品[2] 产品用途 - Cytek Biosciences的产品仅供研究使用，不适用于诊断程序（除了在中国和欧盟可用于临床使用的Northern Lights-CLC系统和某些试剂）[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40632 ______ ...